Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Cystoscopic Local Application of Mitomycin-C following Internal Urethrotomy for Recurrent Short Urethral Strictures in Children: A Preliminary Experience

Ratan SK., Sharma NK., Saxena G., Neogi S.

Prospective Study on Scar, published in J Indian Assoc Pediatr Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Indian Assoc Pediatr Surg (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40756060
PMCID
PMC12316426
DOI
10.4103/jiaps.jiaps_299_24
Citations
1

Abstract (original English)

Background Urethral stricture (US) refers to the scarring process involving the corpus spongiosum (spongiofibrosis). Incidence in children is quite low as compared to adults, with anterior urethra (penile and bulbar) being the most common site. Iatrogenic and posttraumatic causes in the US are more frequent than the idiopathic, infective, and inflammatory causes. Either endoscopic internal urethrotomy (IU) (size 2 cm US) are the main treatment options. However, additional therapy, such as the local application of Mitomycin C (MtMC), improves endoscopic success rates. In the current communication, we present a series of children with recurrent short US ( Materials and methods Five consecutive children with recurrent short US ( n = 2], post fulguration of posterior urethral valves, i.e. iatrogenic US [ n = 2] and congenital US [ n = 1]) underwent treatment by IU and local application of MtMC. Cystoscopic local instillation of 2 ml of MtMC at a concentration of 0.5 mg/ml was done after IU with simultaneous per rectal finger occlusion of the bladder neck. The symptom score (International Prostate Symptom Score [I-PSS]) was utilized in all the patients to gauge the severity of symptoms. Periodic subjective assessment of symptom relief and urinary stream, cystoscopic reassessment for adequacy of intraluminal diameter, ultrasonography, uroflowmetry, retrograde urethrograms, and dimerc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research